• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Enlivex Ltd.

    6/22/26 8:50:17 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENLV alert in real time by email
    6-K 1 ea0295405-6k_enlivex.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

     

    For the month of: June 2026

     

    Commission file number: 001-36578

     

    ENLIVEX LTD.

    (Translation of registrant’s name into English)

     

    14 Einstein Street, Nes Ziona, Israel 7403618

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒        Form 40-F ☐

     

     

     

     

     

     

    On June 22, 2026, Enlivex Ltd., a company organized under the laws of the State of Israel, issued a press release providing an update on its RAIN token holdings. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

     

    Exhibit No.    
         
    99.1   Press Release

     

     1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Enlivex Ltd.
      (Registrant)
       
      By: /s/ Oren Hershkovitz
      Name:  Oren Hershkovitz
      Title: Chief Executive Officer

     

    Date: June 22, 2026

     

     2

    Get the next $ENLV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENLV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Enlivex Ltd.

    3 - Enlivex Ltd. (0001596812) (Issuer)

    3/18/26 7:14:20 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Enlivex Ltd.

    3 - Enlivex Ltd. (0001596812) (Issuer)

    3/18/26 7:15:21 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Enlivex Ltd.

    3 - Enlivex Ltd. (0001596812) (Issuer)

    3/18/26 7:13:06 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    SEC Filings

    View All

    SEC Form 6-K filed by Enlivex Ltd.

    6-K - Enlivex Ltd. (0001596812) (Filer)

    6/24/26 8:01:37 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Enlivex Ltd.

    6-K - Enlivex Ltd. (0001596812) (Filer)

    6/22/26 8:50:17 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Enlivex Ltd.

    6-K - Enlivex Ltd. (0001596812) (Filer)

    5/28/26 8:05:18 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

    Ranked second globally in 24-hour spot trading volume, Gate further extends market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company"), "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that its primary treasury asset, the RAIN token, is expected to be listed on the Gate cryptocurrency exchange, effective June 24, 2026 at 10:00 AM UTC. The listing represents a continued expansion of RAIN’s exchange infrastructure, increasing its accessibility, global reach, and token liquidity.According to Gate

    6/24/26 8:00:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

      As of June 18, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1. Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the ", Company", )), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1. The Company's treasury metrics, as reflected on its public market data dashboard, indicate a Treasury NAV per Share of $4.671 as of June 20, 2026, based on current RAIN token holdings relative to total number of the Company’

    6/22/26 8:45:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

    Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the issuance of an Australian patent, numbered 2020340629, titled, "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS". The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteoarthritis. With this issuance, the Company has secured patent protection for Allocetra™ in osteoarthritis in an additional major jurisdiction, further strengthening its global intellec

    6/15/26 8:00:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Enlivex Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Enlivex Therapeutics with a rating of Buy and set a new price target of $33.00 from $22.00 previously

    3/2/21 6:56:26 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    Leadership Updates

    Live Leadership Updates

    View All

    Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

    As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion.Separately, the Rain Foundation recently announced the appointment of five industry leaders to its advisory board, supporting the next phase of growth of the Rain protocol, the primary digital asset in Enlivex's prediction markets treasury strategy. Nes-Ziona, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the "Company", )), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of May 27, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately

    5/28/26 8:00:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

    Enlivex Announced today $212,000,000 private placement to initiate world's first prediction markets digital asset treasury strategy, via RAIN token accumulation NESS ZIONA, Israel, Nov. 24, 2025 /PRNewswire/ -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV) today announced the appointment of Mr. Matteo Renzi, former Prime Minister of Italy, to the board of directors at Enlivex, effective November 24th. 2025. Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) for the purchase and sale of 212,000,000 ordinary shares (or ordinary share equi

    11/24/25 10:00:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

    - Upon the closing of the private placement, Enlivex will adopt the world's first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - built for transparency, automation, and community participation. - Mr. Matteo Renzi, former Prime Minister of Italy, will be appointed to the Enlivex Board of Directors following closing of the private placement. - Enlivex to continue clinical development of Allocetra™, a potentially game-changing knee osteoarthritis therapeutic, a growing market w

    11/24/25 7:55:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    Financials

    Live finance-specific insights

    View All

    Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

    Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, "Enlivex" or "the Company")), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11:00 am ET. Shai Novik, Executive Chairman of Enlivex, will provide an update on the Company's plans following its recently closed $212,000,000 private placement. Mr. Novik will discuss the launch of Enlivex's digital asset treasury strategy built around RAIN token accumulation as well as the Company's plans to continue to advance the clinical development of AllocetraTM. Virtual Fireside Chat Details Date: December 11, 2025Time: 11:00 am ETRegistration Link:https://shorturl

    12/4/25 8:00:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

    1/10/25 9:00:00 AM ET
    $BIAF
    $ENLV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Enlivex Therapeutics: https://www.redchip.com/assets/access/enlv_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessOren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update.

    7/19/24 9:00:00 AM ET
    $BTCY
    $ENLV
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ENLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Enlivex Therapeutics Ltd.

    SC 13G - Enlivex Therapeutics Ltd. (0001596812) (Subject)

    11/14/24 3:29:35 PM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care